ING Group’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $754K | Buy |
1,432
+919
| +179% | +$515K | ﹤0.01% | 475 |
|
|
2026
Q1 | $288K | Sell |
513
-10,978
| -96% | -$7.04M | ﹤0.01% | 493 |
|
|
2025
Q4 | $7.77M | Buy |
11,491
+11,155
| +3,320% | +$7.6M | 0.05% | 231 |
|
|
2025
Q3 | $215K | Buy |
+336
| New | +$204K | ﹤0.01% | 504 |
|
|
2025
Q2 | – | Sell |
-8,901
| Closed | -$3.74M | – | 530 |
|
|
2025
Q1 | $3.74M | Sell |
8,901
-2,437
| -21% | -$1.06M | 0.03% | 270 |
|
|
2024
Q4 | $4.69M | Sell |
11,338
-5,416
| -32% | -$2.38M | 0.03% | 286 |
|
|
2024
Q3 | $8.46M | Sell |
16,754
-1,848
| -10% | -$898K | 0.05% | 226 |
|
|
2024
Q2 | $9.06M | Sell |
18,602
-1,378
| -7% | -$692K | 0.05% | 242 |
|
|
2024
Q1 | $10.8M | Buy |
19,980
+1,326
| +7% | +$725K | 0.07% | 221 |
|
|
2023
Q4 | $10.4M | Buy |
18,654
+18,048
| +2,978% | +$8.47M | 0.08% | 205 |
|
|
2023
Q3 | $265K | Sell |
606
-1,959
| -76% | -$977K | ﹤0.01% | 498 |
|
|
2023
Q2 | $1.29M | Sell |
2,565
-16,801
| -87% | -$8.05M | 0.01% | 415 |
|
|
2023
Q1 | $9.68M | Buy |
19,366
+3,502
| +22% | +$1.68M | 0.09% | 173 |
|
|
2022
Q4 | $6.47M | Buy |
15,864
+13,879
| +699% | +$5.39M | 0.07% | 205 |
|
|
2022
Q3 | $647K | Sell |
1,985
-7,724
| -80% | -$2.84M | 0.01% | 375 |
|
|
2022
Q2 | $3.4M | Sell |
9,709
-8,639
| -47% | -$3.52M | 0.04% | 309 |
|
|
2022
Q1 | $10M | Buy |
18,348
+3,679
| +25% | +$1.94M | 0.1% | 154 |
|
|
2021
Q4 | $9.66M | Buy |
14,669
+6,029
| +70% | +$3.78M | 0.09% | 182 |
|
|
2021
Q3 | $5.37M | Buy |
8,640
+132
| +2% | +$88.7K | 0.07% | 186 |
|
|
2021
Q2 | $5.37M | Buy |
8,508
+2,852
| +50% | +$1.57M | 0.09% | 152 |
|
|
2021
Q1 | $2.77M | Sell |
5,656
-2
| -0% | -$1K | 0.06% | 191 |
|
|
2020
Q4 | $2.83M | Buy |
5,658
+3,776
| +201% | +$1.69M | 0.06% | 189 |
|
|
2020
Q3 | $740K | Buy |
1,882
+1,164
| +162% | +$430K | 0.03% | 227 |
|
|
2020
Q2 | $237K | Sell |
718
-846
| -54% | -$245K | 0.01% | 248 |
|
|
2020
Q1 | $379K | Sell |
1,564
-4,320
| -73% | -$1.13M | 0.02% | 277 |
|
|
2019
Q4 | $1.54M | Sell |
5,884
-10,000
| -63% | -$2.64M | 0.05% | 243 |
|
|
2019
Q3 | $4.32M | Sell |
15,884
-9,737
| -38% | -$2.71M | 0.11% | 133 |
|
|
2019
Q2 | $7.05M | Buy |
25,621
+99
| +0.4% | +$24.4K | 0.12% | 125 |
|
|
2019
Q1 | $5.71M | Buy |
25,522
+9,932
| +64% | +$2.05M | 0.12% | 113 |
|
|
2018
Q4 | $2.9M | Buy |
15,590
+12,784
| +456% | +$2.62M | 0.06% | 178 |
|
|
2018
Q3 | $701K | Sell |
2,806
-18,481
| -87% | -$4.49M | 0.01% | 431 |
|
|
2018
Q2 | $4.64M | Buy |
21,287
+442
| +2% | +$91.1K | 0.09% | 136 |
|
|
2018
Q1 | $3.99M | Buy |
20,845
+26
| +0.1% | +$4.8K | 0.07% | 150 |
|
|
2017
Q4 | $3.26M | Buy |
20,819
+17,840
| +599% | +$2.81M | 0.05% | 168 |
|
|
2017
Q3 | $463K | Buy |
+2,979
| New | +$471K | 0.01% | 510 |
|
|
2017
Q2 | – | Sell |
-17,037
| Closed | -$2.63M | – | 878 |
|
|
2017
Q1 | $2.63M | Buy |
+17,037
| New | +$2.35M | 0.05% | 213 |
|
Other funds holding IDXX
ING Group's IDXX Position: Q2 2026 in Review
ING Group increased its Idexx Laboratories (IDXX) stake by 179% in Q2 2026, buying an estimated $515K and bringing the position to 1,432 shares worth $754K. The position accounts for ﹤0.01% of the portfolio, ranked #475.
ING Group first reported a position in IDXX in Q1 2017 and has held it in 36 quarters since. The position peaked at $10.8M in Q1 2024. 1,295 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.
- ING Group held 1,432 shares of Idexx Laboratories worth $754K as of Q2 2026.
- ING Group bought 919 Idexx Laboratories shares in Q2 2026, an estimated $515K.
- Idexx Laboratories made up ﹤0.01% of ING Group's portfolio in Q2 2026, its #475 holding.
- ING Group first reported a position in Idexx Laboratories in Q1 2017 and has held it in 36 quarters since.
- ING Group's Idexx Laboratories position peaked at $10.8M in Q1 2024.
- 1,295 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.
Based on ING Group's 13F filing for Q2 2026, filed 13 Aug 2026.